Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Dawn Driscoll"'
Publikováno v:
Stem Cells Translational Medicine, Vol 6, Iss 8, Pp 1723-1729 (2017)
Abstract Cellular therapies and other regenerative medicines are emerging as potentially transformative additions to modern medicine, but likely at a staggering financial cost. Public health care systems’ budgets are already strained by growing and
Externí odkaz:
https://doaj.org/article/e48c15f8affc4c7fb3a473b286a28632
Autor:
Nathan Smith, Rebecca Lim, Bruce L. Levine, Dawn Driscoll, Dominic Wall, Gina D. Kusuma, Anqi Li, David J. James
Publikováno v:
Cytotherapy. 23:774-786
The successful commercialization of cell therapies requires thorough planning and consideration of product quality, cost and scale of the manufacturing process. The implementation of automation can be central to a robust and reproducible manufacturin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052e23bcf6ceb2ff01647c3358117b67
https://doi.org/10.1016/j.jcyt.2021.04.003
https://doi.org/10.1016/j.jcyt.2021.04.003
Publikováno v:
Stem Cells Translational Medicine
Stem Cells Translational Medicine, Vol 6, Iss 8, Pp 1723-1729 (2017)
Stem Cells Translational Medicine, Vol 6, Iss 8, Pp 1723-1729 (2017)
Cellular therapies and other regenerative medicines are emerging as potentially transformative additions to modern medicine, but likely at a staggering financial cost. Public health care systems’ budgets are already strained by growing and aging po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00000efcc29d861d1f90134027d7faa1
https://pubmed.ncbi.nlm.nih.gov/28749065
https://pubmed.ncbi.nlm.nih.gov/28749065
Autor:
Scott R. Burger, Robert J. Deans, Tracey Lodie, René Lardenoije, Mark Bonyhadi, Christopher E. Mason, Dawn Driscoll, Ralf Huss, Timothy E Allsopp, Kurt C. Gunter, Jon A. Rowley, Melissa Carpenter, Tara Clark, John E.J. Rasko, Richard T. Maziarz, Ed Field, Richard Neubiser, Charles S. Cox
Publikováno v:
Cytotherapy. 12(7)
The last decade has seen a dramatic rise in the development of new cellular therapeutics in a wide range of indications. There have been acceptable safety profi les reported in early studies using blood-derived and adherent stem cell products, but al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9d720f23fd562eefbfd3d614ae8915
https://pubmed.ncbi.nlm.nih.gov/20942603
https://pubmed.ncbi.nlm.nih.gov/20942603
Autor:
Richard T. Maziarz, Dawn Driscoll
Publikováno v:
Cell Stem Cell. (6):609-612
As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c004bcd9a08e93eb50c8c4d040554e5c